Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 3/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ic261 SCHEMBL3697594 | 1.00 | CSNK1D (1.00) | CSNK1DCSNK1A1CSNK1EMAPTL3MBTL1 | |
| Ic261 SCHEMBL29467414 | 1.00 | CSNK1D (1.00) | CSNK1DCSNK1A1CSNK1EMAPTL3MBTL1 | |
| Ic261 SCHEMBL2786157 | 1.00 | CSNK1D (1.00) | CSNK1DCSNK1A1CSNK1EMAPTL3MBTL1 | |
| SCHEMBL6000869 | 0.92 | CSNK1D (0.86) | CSNK1DCSNK1A1CSNK1EMAPTL3MBTL1 | |
| SCHEMBL5464433 | 0.87 | CSNK1D (0.78) | CSNK1DCSNK1A1CSNK1EMAPTL3MBTL1 | |
| SCHEMBL5464438 | 0.87 | CSNK1D (0.78) | CSNK1DCSNK1A1CSNK1EMAPTL3MBTL1 | |
| SCHEMBL5469713 | 0.84 | MDM2 (1.00) | CSNK1DCSNK1A1CSNK1EMAPTL3MBTL1 | |
| SCHEMBL14448889 | 0.84 | MDM2 (1.00) | CSNK1DCSNK1A1CSNK1EMAPTL3MBTL1 | |
| SCHEMBL5469718 | 0.84 | MDM2 (1.00) | CSNK1DCSNK1A1CSNK1EMAPTL3MBTL1 | |
| SCHEMBL5472398 | 0.83 | CSNK1D (0.71) | CSNK1DCSNK1A1CSNK1EMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053775-A1 | METHODS, COMPOSITIONS, KITS AND USES THEREOF TARGETING AND/OR TREATING VRK2 TO ENHANCE EFFECTIVENESS OF IMMUNE CHECKPOINT INHIBITOR(S) | UNIV COLUMBIA (US) | 2026-02-26 | — | — | US | claimed |
| US-12491176-B2 | Methods, compositions, kits and uses thereof targeting and/or treating VRK2 to enhance effectiveness of immune checkpoint inhibitor(s) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-12-09 | — | — | US | claimed |
| US-20240398758-A1 | METHODS FOR IDENTIFYING AND USING INHIBITORS OF CASEIN KINASE 1 EPSILON ISOFORM FOR INHIBITING THE GROWTH AND/OR PROLIFERATION OF MYC-DRIVEN TUMOR CELLS | FRED HUTCHINSON CANCER CENTER | 2024-12-05 | — | — | US | claimed |
| US-20240342161-A1 | BISBENZYLISOQUINOLINES AS CONDITIONING AGENTS FOR IMMUNE THERAPY | Escend Pharmaceuticals, Inc. | 2024-10-17 | — | — | US | claimed |
| CN-118574620-A | Method for promoting hair growth | 佛教慈济医疗财团法人 | 2024-08-30 | — | — | CN | claimed |
| US-20240252688-A1 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT BIO CORP. | 2024-08-01 | — | — | US | claimed |
| US-20240228552-A9 | NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING | UNIVERSITY OF MASSACHUSETTS | 2024-07-11 | — | — | US | claimed |
| US-20240189294-A1 | METHOD FOR REGULATING SEBACEOUS GLAND | LIN, CHIN-LON | 2024-06-13 | — | — | US | claimed |
| US-20240132551-A1 | NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING | UNIV MASSACHUSETTS (US) | 2024-04-25 | — | — | US | claimed |
| EP-4351580-A1 | METHOD FOR PREVENTING OR TREATING SKIN DISORDERS AND CONDITIONS | Buddhist Tzu Chi Medical Foundation (TW) | 2024-04-17 | — | — | EP | claimed |
| CN-117813091-A | Method for preventing or treating skin diseases and conditions | 佛教慈济医疗财团法人 | 2024-04-02 | — | — | CN | claimed |
| US-11752151-B2 | Method for enhancing hair growth | BUDDHIST TZU CHI MEDICAL FOUNDATION (TW) | 2023-09-12 | — | — | US | claimed |
| WO-2023056202-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT BIO CORP. (US) | 2023-04-06 | — | — | WO | claimed |
| US-20230053307-A1 | METHOD FOR PREVENTING OR TREATING SKIN DISORDERS AND CONDITIONS | BUDDHIST TZU CHI MEDICAL FOUNDATION (TW) | 2023-02-16 | — | — | US | claimed |
| WO-2023004296-A1 | METHOD FOR PREVENTING OR TREATING SKIN DISORDERS AND CONDITIONS | BUDDHIST TZU CHI MEDICAL FOUNDATION (TW) | 2023-01-26 | — | — | WO | claimed |
| US-20230024910-A1 | METHOD FOR ENHANCING HAIR GROWTH | BUDDHIST TZU CHI MEDICAL FOUNDATION (TW) | 2023-01-26 | — | — | US | claimed |
| WO-2023285974-A1 | METHOD FOR ENHANCING HAIR GROWTH | BUDDHIST TZU CHI MEDICAL FOUNDATION (TW) | 2023-01-19 | — | — | WO | claimed |
| US-20220370408-A1 | METHODS, COMPOSITIONS, KITS AND USES THEREOF TARGETING AND/OR TREATING VRK2 TO ENHANCE EFFECTIVENESS OF IMMUNE CHECKPOINT INHIBITOR(S) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-11-24 | — | — | US | claimed |
| WO-2009047163-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-16 | — | — | WO | claimed |
| US-20090099237-A1 | Methods of treating inflammatory diseases | ROCHE PALO ALTO LLC | 2009-04-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230053307-A1 | METHOD FOR PREVENTING OR TREATING SKIN DISORDERS AND CONDITIONS | PACSIN2, CSNK1A1, CSNK2A3 | CSNK1D 33/4885CSNK1A1 2/4885CSNK1E 12/4885 |
| US-20240189294-A1 | METHOD FOR REGULATING SEBACEOUS GLAND | PACSIN2, CSNK1G1, CSNK2A1 | CSNK1D 45/4885CSNK1A1 4/4885CSNK1E 15/4885 |
| US-20220370408-A1 | METHODS, COMPOSITIONS, KITS AND USES THEREOF TARGETING AND/OR TREATING VRK2 TO ENHANCE EFFECTIVENESS OF IMMUNE CHECKPOINT INHIBITOR(S) | VRK2, VRK1, PDCD1LG2 | CSNK1D 962/4885CSNK1A1 512/4885CSNK1E 555/4885 |
| US-20240342161-A1 | BISBENZYLISOQUINOLINES AS CONDITIONING AGENTS FOR IMMUNE THERAPY | NFATC1, CTNNB1, CAMK1D | CSNK1D 214/4885CSNK1A1 189/4885CSNK1E 274/4885 |
| US-20240398758-A1 | METHODS FOR IDENTIFYING AND USING INHIBITORS OF CASEIN KINASE 1 EPSILON ISOFORM FOR INHIBITING THE GROWTH AND/OR PROLIFERATION OF MYC-DRIVEN TUMOR CELLS | CSNK1E, CSNK1A1, CSNK1G1 | CSNK1D 8/4885CSNK1A1 2/4885CSNK1E 1/4885 |
| US-11752151-B2 | Method for enhancing hair growth | CSNK1A1, CSNK1G1, CSNK2A1 | CSNK1D 20/4885CSNK1A1 1/4885CSNK1E 9/4885 |
| US-20090099237-A1 | Methods of treating inflammatory diseases | CSNK1A1, PACSIN2, CSNK1G1 | CSNK1D 16/4885CSNK1A1 1/4885CSNK1E 5/4885 |
| US-20230024910-A1 | METHOD FOR ENHANCING HAIR GROWTH | CSNK1A1, CSNK1G1, CSNK2A1 | CSNK1D 20/4885CSNK1A1 1/4885CSNK1E 9/4885 |
| US-12491176-B2 | Methods, compositions, kits and uses thereof targeting and/or treating VRK2 to enhance effectiveness of immune checkpoint inhibitor(s) | VRK2, VRK1, PDCD1LG2 | CSNK1D 962/4885CSNK1A1 512/4885CSNK1E 555/4885 |
| US-20260053775-A1 | METHODS, COMPOSITIONS, KITS AND USES THEREOF TARGETING AND/OR TREATING VRK2 TO ENHANCE EFFECTIVENESS OF IMMUNE CHECKPOINT INHIBITOR(S) | VRK2, VRK1, PDCD1 | CSNK1D 660/4885CSNK1A1 552/4885CSNK1E 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.